Physicians' Academy for Cardiovascular Education

EAS 2020

News from the virtual EAS 2020 congress, on Oct 4-7.

A recombinant fusion protein that binds to PCSK9 appears safe and yields effective LDL-c lowering

News - Oct. 13, 2020

EAS 2020 Four-weekly injection of the recombinant fusion protein LIB003 that binds stably to PCSK9 reduced LDL-c, observed in a one year extension study.

Measured Lp(a) levels and LPA GRS similarly associated with ASCVD risk in primary prevention setting

News - Oct. 7, 2020

EAS 2020 In participants of the UK Biobank, a LPA genetic risk score and measured Lp(a) levels provided comparable risk prediction for ASCVD risk in a primary prevention setting.

ANGPTL3 inhibition reduces LDL-c in HoFH patients with limited to no LDL receptor activity

News - Oct. 6, 2020

EAS 2020 Inhibition of ANGPTL3 with evinacumab reduced LDL-c levels significantly in HoFH patients with little to no LDL receptor function.

Huge advantage with ANGPTL3 inhibitor for HoFH patients with minimal to zero LDLR activity

3' education - Oct. 6, 2020 - Prof. Frederick Raal, MD
A post-hoc analysis of the ELIPSE HoFH trial in patients with little to no LDL receptor activity demonstrated a large reduction of LDL-c with the ANGPTL3 inhibitor evinacumab compared to placebo.

EAS 2020 A post-hoc analysis of the ELIPSE HoFH trial in patients with little to no LDL receptor activity demonstrated a large reduction of LDL-c with the ANGPTL3 inhibitor evinacumab compared to placebo.

In high-risk primary prevention individuals, RNAi against PCKS9 reduces LDL-c

News - Oct. 6, 2020

EAS 2020 In a cohort of high-risk primary prevention individuals, 6-monthly injections with inclisiran reduced LDL-c and other atherogenic lipoproteins compared to placebo.

LDL-c lowering by RNAi against PCKS9 similar across HeFH genotype subgroups

News - Oct. 6, 2020

EAS 2020 A subanalysis of ORION-9 showed that lowering of LDL-c by inclisiran was similar across subgroups of genotypes in those with heterozygous FH.

A novel small binding protein that targets PCSK9

3' education - Oct. 6, 2020 - Prof. Evan Stein, MD, PhD
Prof. Stein gives an overview of studies with the small binding protein targeting PCSK9, named LIB003.

EAS 2020 Prof. Stein gives an overview of studies with the small binding protein targeting PCSK9, named LIB003.

Small interfering RNA against PCSK9 reduces LDL-c in HeFH independent of genotype

3' education - Oct. 6, 2020 - Prof. Frederick Raal, MD
A subanalysis of the ORION-9 trial demonstrated that across subgroups of genotypes for HeFH, inclisiran (a small interfering RNA against PCKS9) was equally effective in reducing LDL-c.

EAS 2020 A subanalysis of the ORION-9 trial demonstrated that across subgroups of genotypes for heterozygous FH, inclisiran was equally effective in reducing LDL-c.